Skip to content
‹ Back to IndustriesSciences

Why You Shouldn’t Be Using ‘Conventional’ Methods for Unconventional Drilling

The Sciences Podcast explores the use of big data for both conventional and unconventional reservoirs with insights from geoscientists at Ikon Science. Gabi D’Aubeterre and Yoryenys Del Moro discuss the challenges of unconventional reservoirs, highlighting the need for advanced data techniques. Unconventional drilling requires changing traditional methods to effectively extract hydrocarbons.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · DrillingGabi D’aubeterre PodcastGeopredictionGeoscientist
Share
Why You Shouldn’t Be Using ‘Conventional’ Methods for Unconventional Drilling

Key takeaways

01

Ikon Science experts emphasize the necessity to change traditional methods when dealing with unconventional reservoirs.

02

Big data including seismic and well information is crucial for optimizing production in unconventional drilling.

03

Unconventional reservoirs require advanced techniques to effectively extract hydrocarbons, as traditional trapping mechanisms are absent.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On this episode of the Sciences Podcast, host Tyler Kern dug deep, so to speak, on the topic of using big data for conventional and unconventional reservoirs with two geoscientists from Ikon Science. Today’s guests are Gabi D’Aubeterre], Americas support team manager, and Yoryenys Del Moro, regional product champion for wells.

Del Moro said current methods are just scratching the surface of what kind of production is possible.

“To get more production, … we need to use more data, including seismic and well information,” she said.

Ikon Science develops pioneering GeoPrediction software technology and solutions to help customers have better hit rates and faster production with reduced cost and cycle time. The quantitative interpretation of seismic and well data has been widely successful for conventional operations around the world but lags in unconventional reservoirs, D’Aubeterre and Del Moro said.

“When it comes to unconventional reservoirs, we need to change our mindset from what we’ve done traditionally,” D’Aubeterre said.

Unconventional reservoirs pose a unique challenge for geoscientists. While the rocks in conventional reservoirs effectively traps oil and gas until it’s drilled, this same trapping mechanism is not present in more difficult unconventional plays. In a conventional reservoir, the type of rock (usually a sandstone) traps the hydrocarbon effectively within its porous space, but this is not the case for unconventional reservoirs.

“In an unconventional reservoir, the hydrocarbons do not flow naturally and are trapped within the rock, within low permeability and low porosity units” D’Aubeterre said. Fracturing the rock and shale to extract that oil and gas makes a challenge for geoscientists and engineers.

Del Moro agreed, saying complications exist when geoscientists and engineers look to fracture the right area of rock for the right natural resource to produce hydrocarbons.

“So you need to apply the techniques that allow you to define and detect what you’re looking for in the shales, fractures, and natural fracture zones,” Del Moro said, explaining seismic data allows you to do that.

D’Aubeterre and Del Moro shared specific examples of quantitative interpretation of seismic and well data in unique settings and how the machine learning and integration.

Read more on the Ikon Science Website.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's petosemtamab, added to Merck's Keytruda, cut the risk of death by 50% in 699 first-line head and neck cancer patients. The trial held regardless of HPV status. Full data will be presented at an upcoming medical meeting.

  • 01In a cancer where median survival runs about 10 to 12 months, adding petosemtamab to Keytruda halved the risk of death at the first interim look.
  • 02The benefit held regardless of HPV status, supporting use in PD-L1-positive patients without separating by HPV status.
  • 03The figure to watch at the full-data presentation is median overall survival in each arm, because the topline release reports only the hazard ratio.

Nov 9, 2026

UCB commits to Veeva Vault CRM for unified engagement

UCB commits to Veeva Vault CRM for unified engagement

UCB has committed to Veeva Vault CRM, which Veeva’s release presents as an agentic CRM platform to drive unified engagement worldwide. UCB and Veeva executives describe it as a stable foundation for UCB’s commercial strategy, while the AI claims, including the Agentic Call Report, come from Veeva’s product description. No go-live date or financial terms were given.

  • 01The executive statements focus on Vault CRM as a foundation. The AI pitch, including the Agentic Call Report, comes from Veeva’s product description.
  • 02Veeva says the Agentic Call Report turns field call records into "Commercial Evidence" about treatment barriers that went unseen before. If it works as described, call reports gain value when analyzed at scale.
  • 03No go-live date or financial terms were disclosed. A go-live date or first-market rollout from UCB would show how quickly a worldwide migration is moving.

Nov 7, 2026

Why ISPE put peptide and oligo facility design in one guide

Why ISPE put peptide and oligo facility design in one guide

ISPE's new Baseline Guide covers oligonucleotide and peptide facility design in one document, says Jim Love of CRB. It pairs a GMP survey of existing plants with a sustainability outlook and a piping safety framework for scale-up, while FDA's oligonucleotide guidances under dockets opened in 2022 and 2024 remain the regulator's own reference.

  • 01Peptide plants inherited API chemistry thinking and oligo plants biotech thinking; ISPE’s guide puts both modalities in one facility document with both inheritances.
  • 02The guide has three parts: a GMP survey of existing oligo and peptide plants, a forecast of how sustainability and scale will change the processes, and a safety framework for connective piping and equipment.
  • 03FDA keeps its own oligonucleotide-specific guidances under dockets opened in 2022 and 2024, so the ISPE guide works as an industry consensus alongside regulation rather than in place of it.

Nov 5, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

S
Sciences
GD
Gabi D’Aubeterre

Americas Support Team Manager

Ikon Science

YD
Yoryenys Del Moro

Regional Product Champion for Wells

Ikon Science

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512